ALK and neuroblastoma: NRAS knockdown was confirmed via RT-qPCR and WB (Supplementary Fig. 9A, B) and significantly decreased the ED50 values for both brigatinib and ceritinib in ALK-mutant NB cells (SH-SY5Y) (Supplementary Fig. 9C, D).